1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Autor:	John A. Stewart, Stephan Jacob, Ike Ogbaa, Michael E. Trautmann, Richard E. Pratley, Kun-Ho Yoon, Christopher H. Sorli, Jahoon Kang, Oakpil Han, Marcus Hompesch
Rok vydání:	2019
Předmět:	education.field_of_study medicine.medical_specialty Waist business.industry Endocrinology Diabetes and Metabolism Population medicine.disease Body weight Obesity Diabetes mellitus Internal medicine Baseline characteristics Internal Medicine medicine In patient business education
Zdroj:	Diabetes. 68
ISSN:	1939-327X 0012-1797
DOI:	10.2337/db19-1001-p
Popis:	Once-weekly (QW) subcutaneous efpeglenatide (efpeg) is a long-acting GLP-1 RA being developed to improve glycemic control in patients with T2D. In the BALANCE 205 study (NCT02075281) in patients with obesity (median BMI 34.9 [28.1−57.7] kg/m2) without diabetes, all doses of efpeg (4 or 6 mg QW; 6 or 8 mg once every 2 weeks [Q2W]) significantly reduced body weight (BW) from baseline (BL) to Week 21 vs. placebo (PBO, p In conclusion, all doses of efpeg led to consistent, significant reductions in BW and BMI in patients with obesity without diabetes in all subpopulations tested; results were consistent with those of the overall BALANCE population. Disclosure R.E. Pratley: Consultant; Self; Sanofi US. Other Relationship; Self; AstraZeneca, Eli Lilly and Company, GlaxoSmithKline plc., Janssen Global Services, LLC., Janssen Research & Development, Lexicon Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Mundipharma, Novo Nordisk Inc., Pfizer Inc., Sanofi, Takeda Development Center Americas, Inc. S. Jacob: Advisory Panel; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Novo Nordisk A/S. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Novartis AG, Novo Nordisk A/S, Roche Diabetes Care, Sanofi. J. Kang: Employee; Self; Hanmi Pharm. Co., Ltd. M.E. Trautmann: Consultant; Self; CeQur Corporation, Hanmi Pharm. Co., Ltd., Intarcia Therapeutics, Inc., Oramed Pharmaceuticals, ProSciento, Servier. Stock/Shareholder; Self; Lilly Diabetes. M. Hompesch: Stock/Shareholder; Self; ProSciento. O. Han: None. J.A. Stewart: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. I. Ogbaa: Stock/Shareholder; Self; Lexicon Pharmaceuticals, Inc. Other Relationship; Self; Sanofi. C.H. Sorli: Employee; Self; Sanofi. K. Yoon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Inc. Speaker's Bureau; Self; Takeda Pharmaceutical Company Limited. Funding Hanmi Pharmaceutical, Co., Ltd.; Sanofi
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::bc6691877d13da5216f909b2b46c2ee2 https://doi.org/10.2337/db19-1001-p Zobrazit plný text záznamu